TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01635894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Women in both the practice nurse and specialist nurse groups were given supervised pelvic floor exercise training. After the initial training they were given a daily exercise regimen and seen at monthly intervals for three months. The practice nurses had attended a study day on supervising Pelvic Floor Muscle Training(PFMT)followed by practice sessions with patients overseen by the nurse specialist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Women in both the practice nurse and specialist nurse groups were given supervised pelvic floor exercise training. After the initial training they were given a daily exercise regimen and seen at monthly intervals for three months. The practice nurses had attended a study day on supervising Pelvic Floor Muscle Training(PFMT)followed by practice sessions with patients overseen by the nurse specialist.
Study: NCT04497311

Intervention type: DIAGNOSTIC_TEST
Intervention: Thoraxic computed tomography
Description: Diagnostic lung CT.
Study: NCT04297774

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: balance training
Description: 18 balance training sessions (30 minutes a time, 2-3 times a week) (1) Facilitated the balance reaction through weight shifting exercise with standing on even surface to uneven surface, such as tilting board.(2) Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. (3) Changed the standing requirement, such as single legged stance or lunge stance. (4) Increased perception complications through cognition or upper extremity task to improve dual task attention.
Study: NCT02542280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial injury.
Description: Endometrial injury using a pipelle biopsy catheter on day (5, 6 or 7) of the stimulation cycle combined with the intrauterine insemination.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intrauterine insemination
Description: Placement of washed sperm in the uterus using a catheter, around the time of ovulation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrauterine insemination
Description: Placement of washed sperm in the uterus using a catheter, around the time of ovulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ovarian stimulation
Description: Inducing ovulation by human menopausal gonadotrophin ampoules given intramuscular starting from cycle day two, till the leading follicle reaches 16 - 18 mm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ovarian stimulation
Description: Inducing ovulation by human menopausal gonadotrophin ampoules given intramuscular starting from cycle day two, till the leading follicle reaches 16 - 18 mm.
Study: NCT01688791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide
Study: NCT01739517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven Therapy
Description: After baseline labs, which have been collected no earlier than seven days prior to the initiation of therapy are obtained, therapy with Omegaven will be initiated at a starting dose of 0.5 g/kg/day infused over 12 hours. If tolerated, the dose will be increased to 1 g/kg/day, the goal dose. Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
Study: NCT03099785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifamycin SV 600mg t.i.d.
Description: Morning: one 600 mg tablet Afternoon: one 600 mg tablet Evening: one 600 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifamycin SV b.i.d. + Placebo
Description: Morning. one 600 mg tablet Afternoon: one matching placebo tablet Evening: one 600 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo t.i.d.
Description: Morning. one matching placebo tablet Afternoon: one matching placebo tablet Evening: one matching placebo tablet
Study: NCT03805360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine is a local anesthetic that is expected to provide numbness to the chest wall when injected into the erector spinae plane.
Study: NCT01688791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT03014661

Intervention type: OTHER
Intervention: Quality of life under or after therapy with Pollinex quattro
Description: To measure Quality of life using the DLQI-index in year one, year two, year three or six month after therapy with Pollinex quattro plus.
Study: NCT00204893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium formate
Description: Calcium formate - Each uncoated white tablet will contain 650 mg of calcium formate, (equivalent to 200 mg elemental calcium). Nephro-Tech, LLC, will formulate and provide the calcium formate tablets for the study.
Study: NCT02937103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD123-CAR-transduced T cells
Description: The first 3 enrolled patients will receive autologous-derived CD123-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
Study: NCT01688791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT03805360

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: Normal Saline Flush, 0.9% Injectable Solution is not expected to provide numbness to the chest wall when injected into the erector spinae plane.
Study: NCT01582282

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: fiber-free placebo
Study: NCT02392455

Intervention type: DRUG
Intervention: treatment
Description: Docetaxel plus nintedanib until progression or intolerability
Study: NCT04376476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: blood samples will be taken as below: Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: blood samples will be taken as below: Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: blood samples will be taken as below: Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0
Study: NCT01582282

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3.4 g psyllium BID
Description: 3.4 g psyllium BID for a total of 6.8 g/day (10.4g Metamucil)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 6.8g psyllium BID
Description: 6.8g psyllium BID for a total of 13.6 g/day (20.8g Metamucil)
Study: NCT04376476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low or upper respiratory tract sample
Description: Low or upper respiratory tract sample will be collected in order to take virology measurements:~Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low or upper respiratory tract sample
Description: Low or upper respiratory tract sample will be collected in order to take virology measurements:~Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low or upper respiratory tract sample
Description: Low or upper respiratory tract sample will be collected in order to take virology measurements:~Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stool collection or fecal swab
Description: The stool collection or fecal swab will be collected in order to take virology measurements:~Group E1: / Group E2: At day 0, day 7, day 14 Group E3: At day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stool collection or fecal swab
Description: The stool collection or fecal swab will be collected in order to take virology measurements:~Group E1: / Group E2: At day 0, day 7, day 14 Group E3: At day 0

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone call
Description: phone calls will be performed to collect data regarding patients' symptoms at: Group E1: Day 14 Group E3: Day 14

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone call
Description: phone calls will be performed to collect data regarding patients' symptoms at: Group E1: Day 14 Group E3: Day 14
Study: NCT02106767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 20mg po x1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin plus rifampin
Description: Rifampin 600mg IV infused over 30 minutes followed by rosuvastatin 20mg PO x1
Study: NCT03796689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone-linked HBPM and associated app
Description: Participants in the Smartphone-linked arm of the study will receive an Omron 786N Home Blood Pressure Monitor (HBPM) that can be linked to the Omron Connect app via Bluetooth. They will also receive instructions about how to use their device and download the app and will be provided with publicly available guidelines for HBPM. Participants will be instructed to use their device and app to take readings which they can track over time and share with their provider using the app.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard HBPM
Description: Participants in the Standard arm of the study will receive an Omron 785N Home Blood Pressure Monitor (HBPM), instructions about how to use their device and publicly available guidelines for HBPM. They will be instructed to use their device to take readings which they can track over time and share with their provider.
Study: NCT04252937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrecizumab
Description: HAM8101 (Adrecizumab) is a humanized IgG1 monoclonal antibody (mAb).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrecizumab
Description: HAM8101 (Adrecizumab) is a humanized IgG1 monoclonal antibody (mAb).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrecizumab
Description: HAM8101 (Adrecizumab) is a humanized IgG1 monoclonal antibody (mAb).
Study: NCT00414414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03504605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online self-compassion intervention
Description: Parents are asked to write in an online text box about a parenting event in which they felt shame. They are then given a validated set of instructions asking them to reflect on the event and write self-compassionate responses.
Study: NCT01055886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patch
Description: Nicotine patch, 7-21 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: placebo patch used from weeks 4-6
Study: NCT03261817

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity (APA)
Description: 2 sessions a week of 1 hour during 16 weeks. APA exercises by web will be aerobic type associated with muscle toning program; Activities will combine relaxation techniques, body expression and muscle relaxation (yoga, stretching, relaxation, step etc ...).~The intensity of the activities will be individualized for each participant according to his/her physical condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity (APA)
Description: 2 sessions a week of 1 hour during 16 weeks. APA exercises by web will be aerobic type associated with muscle toning program; Activities will combine relaxation techniques, body expression and muscle relaxation (yoga, stretching, relaxation, step etc ...).~The intensity of the activities will be individualized for each participant according to his/her physical condition

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health Education program (HE)
Description: 2 sessions a week of 1 hour during 16 weeks HE by web will be delivered and was composed of information on the main mental disorders, the benefits of physical activity, healthy lifestyle (dietary balance, sleep cycle, stress management), alcohol, drug, tobacco and cardiovascular risk factors

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health Education program (HE)
Description: 2 sessions a week of 1 hour during 16 weeks HE by web will be delivered and was composed of information on the main mental disorders, the benefits of physical activity, healthy lifestyle (dietary balance, sleep cycle, stress management), alcohol, drug, tobacco and cardiovascular risk factors
Study: NCT03483350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: Ampoule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: Ampoule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Ampoule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Ampoule
Study: NCT04284007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perineural levobupivacaine
Description: Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone in addition to levobupivacaine
Description: Patients will receive 20 ml of 0.25% levobupivacaine plus 4mg dexamethasone diluted in 2 ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.
Study: NCT03406429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS
Description: All study participants will receive one block of active rTMS. Each block will consist of daily sessions of 20Hz active rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM rTMS
Description: All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of 20Hz SHAM rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).
Study: NCT02991287

Intervention type: PROCEDURE
Intervention: Inguinal hernia repair
Study: NCT00814073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Description: Masitinib 6 mg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglicate, antidepressants, leukotriene antagonists, interferon-alpha, 2-CdA, and corticosteroids.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglicate, antidepressants, leukotriene antagonists, interferon-alpha, 2-CdA, and corticosteroids.
Study: NCT02991287

Intervention type: PROCEDURE
Intervention: Abdominal hysterectomy
Study: NCT02031380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open angle glaucoma - iDropper device
Description: The iDropper system is an eye drop dispensing device and medication monitor designed to optimize adherence behaviors for glaucoma patients.
Study: NCT02991287

Intervention type: PROCEDURE
Intervention: Vaginal hysterectomy
Study: NCT00400933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psycho-education
Description: six session psycho-educational group program for family members and close friends of persons with eating disorders and co-morbid personality disorders
Study: NCT03736837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Plus Icotinib
Description: Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent.
Study: NCT00371033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: dosage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dosage
Study: NCT02490150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corifollitropin alfa
Study: NCT02991287

Intervention type: PROCEDURE
Intervention: Thoracotomy
Study: NCT03623711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: participants take escitalopram tablets based on their severity of depression (10-20mg/day) at least for 12 weeks.
Study: NCT04359823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin 2%, 2% Cholesterol Cream
Description: Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin 2% Cream
Description: Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
Study: NCT00540176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Description: Oral DCA given twice daily for the 24 week period of the study. Continuation of therapy will be indefinite if efficacious.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Description: Oral DCA given twice daily for the 24 week period of the study. Continuation of therapy will be indefinite if efficacious.
Study: NCT03714386

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A synthetic high-flux dialyzer will be used for OL-HDF.
Description: A synthetic high-flux dialyzer used for OL-HDF must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A medium cut-off dialyzer will be used for HDx.
Description: A medium cut-off dialyzer used for HDx must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
Study: NCT01958034

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bilberry extract
Study: NCT02991053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Study: NCT03623711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: participants take Duloxetine capsule based on their severity of depression (60mg/day) at least for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: participants take Bupropion tablets based on their severity of depression (75-300mg/day) at least for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Healthy control
Description: Healthy control take placebo tablets
Study: NCT01977976

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial aspiration by pipelle
Description: Endometrial aspiration by pipelle is to be performed on LH+7 in the cycle preceding scheduled IVF treatment
Study: NCT00855166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablet oral 10 mg total daily dose once daily 102 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablet oral 1500 - 2500 mg total daily dose 1-3 times a day104 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Tablet oral 1500 - 2500 mg total daily dose 1-3 times a day104 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Tablet oral 100 mg total daily dose once daily rescue medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: Tablet oral 100 mg total daily dose once daily rescue medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for dapagliflozin, tablet, oral, once daily, 102 weeks
Study: NCT02478749

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arm retraction
Description: gently pulling through the ipsilateral arm to the knee
Study: NCT02478749

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arm retraction
Description: gently pulling through the ipsilateral arm to the knee

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arm retraction
Description: gently pulling through the ipsilateral arm to the knee
Study: NCT03725527

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus Sheath Block
Description: Sonar guided RSB will be performed using a 16-G, 8-cm TuohyUpon reaching this potential space, after careful aspiration.
Study: NCT01272258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140
Description: SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection
Study: NCT00489476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Staccato Loxapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Staccato Loxapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Staccato Loxapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Staccato Placebo
Description: Placebo aerosol inhalation (0mg)
Study: NCT02011542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3
Description: This is a probiotic mixture

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a pill with inactive ingredients.
Study: NCT03248661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Now I'm Telling You
Description: Messages will be sent trough Facebook, Twitter, Instagram, e-mail, texting or other electronic/social media specified by study volunteers.
Study: NCT03503994

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled Beclomethasone Dipropionate Monohydrate
Description: Beclomethasone Dipropionate (HFA-BDP, QVAR\*) in the following doses will be evaluated:~1. 200 mcg bid~2. 400 mcg bid~3. 600 mcg bid~4. 800 mcg bid